Evofem Biosciences, Inc. (EVFM)
0.0067
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Evofem Biosciences Net Income (Quarterly) : -11.04M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.04M |
| March 31, 2026 | -5.465M |
| December 31, 2025 | 2.788M |
| September 30, 2025 | -1.569M |
| June 30, 2025 | -1.784M |
| March 31, 2025 | 0.956M |
| December 31, 2024 | -3.037M |
| September 30, 2024 | -2.365M |
| June 30, 2024 | 1.351M |
| March 31, 2024 | -4.809M |
| December 31, 2023 | -2.114M |
| September 30, 2023 | 66.00M |
| June 30, 2023 | -8.558M |
| March 31, 2023 | -2.354M |
| December 31, 2022 | -8.336M |
| September 30, 2022 | 89.51M |
| June 30, 2022 | -125.98M |
| March 31, 2022 | -31.89M |
| December 31, 2021 | -51.55M |
| September 30, 2021 | -74.06M |
| June 30, 2021 | -33.43M |
| March 31, 2021 | -46.15M |
| December 31, 2020 | -40.60M |
| September 30, 2020 | -29.90M |
| June 30, 2020 | -52.67M |
| Date | Value |
|---|---|
| March 31, 2020 | -19.15M |
| December 31, 2019 | -12.72M |
| September 30, 2019 | -13.80M |
| June 30, 2019 | -35.45M |
| March 31, 2019 | -18.07M |
| December 31, 2018 | -14.98M |
| September 30, 2018 | -18.43M |
| June 30, 2018 | -23.24M |
| March 31, 2018 | -69.06M |
| December 31, 2017 | -19.49M |
| September 30, 2017 | -74.03M |
| June 30, 2017 | -6.512M |
| March 31, 2017 | -5.269M |
| December 31, 2016 | -1.972M |
| September 30, 2016 | -2.362M |
| June 30, 2016 | -2.658M |
| March 31, 2016 | -6.027M |
| December 31, 2015 | -9.515M |
| September 30, 2015 | -17.26M |
| June 30, 2015 | -9.477M |
| March 31, 2015 | -6.902M |
| December 31, 2014 | -2.897M |
| September 30, 2014 | -4.041M |
| December 31, 2013 | -2.791M |
| September 30, 2013 | -2.192M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 2.633M |
| Total Expenses (Quarterly) | 13.67M |
| EPS Diluted (Quarterly) | -0.0811 |
| Enterprise Value | 59.95M |
| Gross Profit Margin (Quarterly) | 80.06% |
| Profit Margin (Quarterly) | -419.1% |
| Earnings Yield | -1.71K% |
| Normalized Earnings Yield | -1108.96 |